Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
February 18, 2022 17:25 ET
|
Ocugen
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and...
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
January 27, 2022 09:25 ET
|
Ocugen
Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companiesCOVAXIN™...
COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2
January 12, 2022 06:43 ET
|
Ocugen
Booster dose of candidate vaccine, COVAXIN™ (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay100%...
Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference
January 06, 2022 18:03 ET
|
Ocugen
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
December 15, 2021 06:46 ET
|
Ocugen
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infectionImmune memory against conserved nucleoprotein may provide an added...
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
November 26, 2021 07:01 ET
|
Ocugen
MALVERN, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines,...
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
November 05, 2021 06:38 ET
|
Ocugen
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health OrganizationPediatric EUA submission based on immuno-bridging clinical trial in children, ages 2-18, demonstrating...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
October 27, 2021 06:35 ET
|
Ocugen
MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines,...
Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™
July 15, 2021 07:34 ET
|
Ocugen
MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness...
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
July 02, 2021 17:42 ET
|
Ocugen
Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variantAdverse...